Drug Trial Radar · NCT00099242
Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: Oct 13, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,040
Actual
Start
Nov 2003
Primary completion
Not stated
Study completion Jan 2006
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 10, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.
Conditions
- Alzheimer's Disease
- Dementia, Alzheimer Type
Interventions
rivastigmine transdermal patchDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in cognition from baseline at week 24
- Global clinical impression of change from baseline at week 24
Locations
75 sites in 21 countries. Site status is shown where the registry gives one.
Site not named
Orange, California
Site not named
San Francisco, California
Site not named
Boca Raton, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Miami, Florida
Site not named
Miami Beach, Florida
Site not named
Port Charlotte, Florida
Site not named
West Palm Beach, Florida
Site not named
Snellville, Georgia
Site not named
St Louis, Missouri
Site not named
Omaha, Nebraska
Site not named
Long Branch, New Jersey
Site not named
Toms River, New Jersey
Site not named
Whiting, New Jersey
Site not named
Columbus, Ohio
Site not named
Dayton, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Greensburg, Pennsylvania
Site not named
Nashville, Tennessee
Site not named
Austin, Texas
Site not named
Houston, Texas
Site not named
Tacoma, Washington
Site not named
Santiago, Chile
Site not named
Valparaíso, Chile
Site not named
Brno, Czechia
Site not named
Brno-Bohunice, Czechia
Site not named
Hradec Králové, Czechia
Site not named
Olomouc, Czechia
Site not named
Prague, Czechia
Site not named
Copenhagen, Denmark
Site not named
Glostrup Municipality, Denmark
Site not named
Hillerød, Denmark
Site not named
Kuopio, Finland
Site not named
Investigative Sites, Germany
Site not named
Guatemala City, Guatemala
Site not named
Beersheva, Israel
Site not named
Haifa, Israel
Site not named
Jerusalem, Israel
Site not named
Petah Tikva, Israel
Site not named
Tel Aviv, Israel
Showing 40 of 75 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.